fusion" and "bilateral motor weakness" refer to. Confusion is a vague term, but it is a frequent complaint of patients experiencing SSRI discontinuation syndrome (2, 3) . Delirium has occasionally been reported with SSRI termination (4) , and it is reasonable to postulate that delirium is more likely to occur in an elderly person such as this patient, in whom the central nervous system (CNS) is already compromised by cerebrovascular changes. With regard to bilateral motor weakness, the patient's confusion and ataxia may have hindered objective assessment of motor power, particularly if fatigue and muscle aches-common SSRI discontinuation symptoms (2,3)were present. Irrespective of this, we have observed muscular weakness in patients experiencing antidepressant discontinuation syndrome (5) .
The rapid and complete resolution of symptoms on restating paroxetine is characteristic of a discontinuation syndrome and implies a reversible neurochemical etiology (6) . These features suggest that irreversible CNS ischemia (that is, stroke) is an improbable mechanism. That the 2 MRI scans showed no progression of the ischemic changes, despite the patient's experiencing a second episode of discontinuation syndrome in the intervening period, also suggests that stroke was not the underlying mechanism and that the ischemic changes on the original MRI scan were coincidental. Dr Ramassubu suggests that the strokes may have occurred secondary to anxiety and elevated blood pressure experienced during the discontinuation syndrome (1) . However, in a study specifically designed to characterize SSRI discontinuation syndrome, little variation in blood pressure was observed despite high rates of discontinuation symptoms (7) . SSRI treatment may occasionally cause cerebral vasoconstriction (8) , but the corollorary is that, if vascular changes occurred on SSRI stoppage, one would expect to see vasodilation. Dr Ramasubbu reports an interesting case. However, the clinical features are not consistent with a stroke, and further, there is no convincing mechanism by which SSRI discontinuation syndrome could cause stroke. In our view, the importance of Dr Ramasubbu's case is that it demonstrates how antidepressant discontinuation symptoms can easily be misdiagnosed. We have encountered such symptoms misdiagnosed as adverse effects of a newly started antidepressant (9), as stroke (5), as influenza, as labyrnthitis, and as relapse and exacerbation of the underlying psychiatric illness.
Re: Depression, Stroke Diagnosis, and SSRI Discontinuation Syndrome
Dear Editor:
I read with great interest Dr Ramasubbu's and Dr Patten's article on the effects of depression on stroke morbidity and mortality (1), as well as Dr Ramasubbu's letter in the same issue about minor strokes related to paroxetine discontinuation (2) . Together, these reports provoke much thought about the role of selective serotonin reuptake inhibitors (SSRIs) in preventing stroke and the complications of stroke. Dr Ramasubbu reported an association between depressive symptoms and increased risk of stroke morbidity and mortality (1) . Alternatively, in addition to an association with SSRI discontinuation syndrome, withdrawal of antidepressants such as paroxetine may create a clinical picture similar to a minor stroke. In their double-blind, placebocontrolled study of sertraline and the prevention of depression in stroke patients, Rassmussen and others reported that the prophylactic use of sertraline prevented the development of depression in poststroke patients (3) . They also reported that patients given sertraline experienced fewer cardiovascular and noncardiovascular adverse events than patients treated with placebo. While there is room for much speculation about the mechanism by which SSRIs reduce the risk of stroke and cardiovascular events, a factor that may bear further consideration is the direct effect of SSRIs on platelets. SSRIs induce reduced platelet adhesion and activity, as has been noted by Musselman and colleagues (4) . Further clinical evidenced is summarized by Dalton and others (5) . In a community-based study, Dalton found that SSRIs, but not non-SSRIs, were associated with significantly increased risk of gastrointestinal bleeding, particularly with the concomitant use of nonsteroidal antiinflammatory drugs.
In essence, depression, which is a well-established risk factor for the development of cardiovascular disease (6), can now be considered as a risk factor for cerebrovascular disorders. The SSRIs' ability to inhibit platelet adhesion, independent of their effect on mood, may be the causative agent. Whether response to depression is necessary for this added benefit has not been established.
If these observations are supported by further studies, we now also have another factor to consider in the selection of antidepressants. Patients who may be at increased risk for cardiovascular or cerebrovascular events may be better served by SSRIs as a drug of first choice. Alternatively, a non-SSRI agent may be the drug of first choice in the treatment of depression for those patients who are on nonsteriodal antiinflammatory drugs.
Reply: Depression, Stroke Diagnosis, and SSRI Discontinuation Syndrome
Dear Editor: I thank Dr Haddad and Dr Dursun for their interest in my case report (1) and for giving me an opportunity to address and discuss their concerns regarding whether physical symptoms related to paroxetine discontinuation were misdiagnosed as minor strokes. They assert that the manifested ataxia and bilateral motor weakness may have been be related to the physical symptoms of selective serotonin reuptake inhibitor (SSRI) discontin-uation syndrome and were unlikely to be caused by minor strokes.
As pointed out in the discussion, brain ischemia (that is, minor strokes) could better account for the neurological symptoms than could coexisting discontinuation syndrome, for several reasons. First, apart from 2 ischemic events following paroxetine discontinuation, the patient had presented to the emergency department with numerous episodes of transient ischemic attacks (TIA) involving vertebrobasilar territory. But on only 2 occasions were the motor weakness and ataxia that occurred following discontinuation of paroxetine considered serious enough to warrant admission to the hospital. Given the evidence of cerebrovascular disease with recurrent TIAs, cardiovascular risk factors, and magnetic resonance imaging (MRI) findings, the neurological symptoms were clinically judged to be directly related to brain ischemia. Moreover, it is necessary to rule out a primary neurological condition such as stroke prior to considering neurological symptoms as physical symptoms of discontinuation syndrome (2) . I admit that the objective assessment of motor power can be clinically challenging when the patient is agitated and tired. However, on repeat evaluations after the admission, the determination and documentation of motor weakness, pyramidal signs, and ataxia were consistent. Although "confusion" is a vague term, it is still frequently used in emergency to describe disorientation and muddled thinking. It is possible that both brain ischemia and discontinuation syndrome could have contributed to delirium.
The time course of symptom resolution for both discontinuation syndrome and minor strokes certainly overlapped in this patient. As with discontinuation syndrome, minor strokes are time-limited and reversible. The lack of progression in MRI findings was cited as the evidence against minor strokes. However, the patient's clinical chart indicated that, during the second episode, cognitive symptoms as well as neurological symptoms definitely worsened and that recovery was incomplete, with residual deficits (This was not discussed in my case report, owing to lack of space.) Possibly overlapping symptoms (for example, delirium, weakness, and ataxia) and time course for symptom resolution between SSRI discontinuation syndrome and minor strokes may have complicated the identification of cooccurring stroke in SSRI discontinuation syndrome. Ruling out minor strokes in this patient with severe cerebrovascular disease remains virtually impossible.
The cooccurrence of SSRI discontinuation and minor strokes does not necessarily imply a causal relation and may be coincidental. The biological mechanisms suggesting a cause-effect relation between SSRI discontinuation and stroke remain largely speculative. Catecholamine activation and the related increase in blood pressure and decrease in cerebrovascular reserve have been postulated as possible mechanisms (1). Although blood pressure variation is seldom reported in SSRI discontinuation syndrome in healthy patients, this observation can not be generalized to a elderly patient with hypertension and cerebrovascular disease. Further, stimulation of the catecholamine system seems to induce platelet activation (4) . Platelet activation may lead to platelet adhesion, aggregate formation, microembolization, release of granular constituents, thromboxane A 2 formation, and vascular occlusion (5) . Hence, platelet activation may play an important role in acute cerebrovascular events. Further, recent evidence suggests that paroxetine may have a protective effect against thrombotic vascular events, attributable to the inhibitory effect of SSRIs on serotoninmediated platelet activation (6) . More studies are required to examine the time course for the reversibility of the antiplatelet effect after acute discontinuation and the role of platelet activation on stroke-like symptoms in SSRI discontinuation syndrome.
Dr
McNevin's views about the role of depression in the development of ischemic stroke and the effect of SSRI treatment in preventing stroke are consistent with emerging literature on this subject (7, 8) . He rightly points out that SSRIs may play a role in preventing ischemic vascular events such as myocardial infarction (MI) and stroke (8) . Taking into account that depression may increase the risk for ischemic stroke (7) and that platelet activation is associated with depression and stroke (9,10), it is
